Alnylam Pharmaceuticals (NASDAQ:ALNY) Given Neutral Rating at Cantor Fitzgerald
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report)‘s stock had its “neutral” rating restated by equities researchers at Cantor Fitzgerald in a report released on Tuesday, Benzinga reports. They presently have a $165.00 price objective on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective would suggest a potential upside of 6.63% from the stock’s previous close. […]
More Stories
Seizert Capital Partners LLC Sells 1,652 Shares of Alphabet Inc. (NASDAQ:GOOGL)
Seizert Capital Partners LLC decreased its position in shares of Alphabet Inc. (NASDAQ:GOOGL – Free Report) by 1.6% during the...
Alphabet Inc. (NASDAQ:GOOGL) Stock Position Trimmed by Symphony Financial Services Inc.
Symphony Financial Services Inc. decreased its position in Alphabet Inc. (NASDAQ:GOOGL – Free Report) by 16.7% in the 4th quarter,...
Sterling Infrastructure, Inc. (NASDAQ:STRL) Shares Purchased by Zurcher Kantonalbank Zurich Cantonalbank
Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Sterling Infrastructure, Inc. (NASDAQ:STRL – Free Report) by 13.8% during...
Paragon Private Wealth Management LLC Buys 868 Shares of JPMorgan Chase & Co. (NYSE:JPM)
Paragon Private Wealth Management LLC grew its stake in JPMorgan Chase & Co. (NYSE:JPM – Free Report) by 26.1% in...
Independent Advisor Alliance Takes Position in Carvana Co. (NYSE:CVNA)
Independent Advisor Alliance bought a new position in shares of Carvana Co. (NYSE:CVNA – Free Report) during the 4th quarter,...
Independent Advisor Alliance Purchases 11,127 Shares of JPMorgan Chase & Co. (NYSE:JPM)
Independent Advisor Alliance lifted its position in shares of JPMorgan Chase & Co. (NYSE:JPM) by 6.5% in the fourth quarter,...